Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705)

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 46-52

  Ogura, Michinori ^a,k   Itoh, Kuniaki ^b   Ishizawa, Kenichi ^c   Kobayashi, Yukio ^d   Tobinai, Kensei ^d   Kinoshita, Tomohiro ^a,e   Hirano, Masami ^f   Ueda, Ryuzo ^g   Shibata, Taro ^h   Nakamura, Shigeo ^a,l   Tsukasaki, Kunihiro ⁱ   Hotta, Tomomitsu ^h,j   Shimoyama, Masanori ^d   Morishima, Yasuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^h NATIONAL CANCER CENTER   (Japan)

ⁱ NAGASAKI UNIVERSITY   (Japan)

^j TOKAI UNIVERSITY   (Japan)

^k NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^l NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

ABV therapy followed by IFRT; First line chemotherapy; Hodgkin lymphoma; Phase II study

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ESOPHAGITIS; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; HYPOXEMIA; JAPAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 84870946988     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.705000     Document Type: Article

References (24)

1. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970 ; 73: 881-895.
2. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252- 259.
3. C anellos G P, A nderson J R, P ropert K J, et al. C hemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478- 1484.
4. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 2003; 21: 607- 614. (Pubitemid 46621893)
5. The World Health Organization classifi cation of malignant lymphomas in Japan: Incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000; 50: 696- 702.
6. J emal A, S iegel R, W ard E, et al. C ancer statistics, 2 008. C A Cancer J Clin 2008; 58: 71-96.
7. Takenaka T, Mikuni C, Miura A, et al. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: A multicenter phase II study (JCOG 8905). Jpn J Clin Oncol 2000; 30: 146-152. (Pubitemid 30335839)
8. Connors JM. Is cyclic chemotherapy better than standard fourdrug chemotherapy for Hodgkin's disease? Yes.Important Adv Oncol 1993: 189-195.
9. Ogura M, Itoh K, Kinoshita Tet al. P hase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin's lymphoma: Japan Clinical Oncology Group study (JCOG9305). Int J Hematol 2010; 92: 713- 724.
10. Costanzi JJ. DTIC (NSC-45388) studies in the Southwest Oncology Group. Cancer Treat Rep 1976; 60: 189- 192.
11. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin' s disease. Cancer Res 1966; 26: 1063- 1083.
12. Carbone PP, Kaplan HS, Musshoff K, et al. R eport of the committee on Hodgkin's disease staging classifi cation. Cancer Res 1971; 31: 1860-1861.
13. Lister TA, Crowther D, Sutcliff e SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636. (Pubitemid 19272832)
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655. (Pubitemid 13149996)
15. Jaff e ES, Harris NL, Stein H, et al. World Health Organization classifi cation of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, 3rd ed. Lyon, France: IARC Press; 2001.
16. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250-257.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
18. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease.International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
19. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPPABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395. (Pubitemid 36682817)
20. Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: Results of the second interim analysis of the GHSG HD13 trial. Haematologica 2010; 95(Suppl.2): Abstract 1146.
21. S traus D J, P ortlock C S, Q in J, et al. R esults of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483-3489. (Pubitemid 39564416)
22. Canellos GP, Duggan D, Johnson J, et al. How important is bleomycin in the adriamycin bleomycin vinblastine dacarbazine regimen? J Clin Oncol 2004; 22: 1532-1533. (Pubitemid 41103643)
23. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-fi eld radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-2406. (Pubitemid 36682818)
24. Scholz M, Engert A, Franklin J, et al. Impact of fi rst- and secondline treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL - experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Ann Oncol 2011; 22: 681-688.